Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00907101 · ClinicalTrials.gov registry record · Phase 4
Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes
A Phase 4 study of P Acnes Colonization, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00907101: Completed Phase 4 study of P Acnes Colonization, sponsored by Galderma R&D.
NCT00907101 is a Phase 4 study of P Acnes Colonization that has completed, run by Galderma R&D. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00907101, a Phase 4 study of P Acnes Colonization, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing antibiotic sensitive and resistant strains of P acnes in vivo.
Primary Outcome
Mean log10 values of P. acnes from swabbed skin samples Please note: Quantitative bacteriologic cultures were obtained from the facial skin (forehead) at screening, baseline, week 2 and week 4/early termination. Samples were obtained according to a modification of the technique of Williamson and Kligman. CFUs of P. acnes were counted at the dilution that contained between 10 and 100 CFUs. Total densities of P. acnes were calculated and reported as the average (of both plates) of the log10 CFUs p
Conditions Studied
Interventions
- DRUG Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
Study Locations (1)
Pennsylvania
- Skin Study Center - Broomall
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
What the finished NCT00907101 record still lists
NCT00907101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with P Acnes Colonization appearing as the primary indexed condition, and to 1 intervention - of which Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel) is the first listed.
NCT00907101 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00907101 about?
NCT00907101 is a clinical study titled "Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes". The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing antibiotic sensitive and resistant strains of P acnes in vivo.
What is the current status of trial NCT00907101?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2009-06. Estimated completion is 2009-07.
What conditions does trial NCT00907101 study?
This clinical trial studies the following conditions: P Acnes Colonization.
What interventions are being tested in trial NCT00907101?
The interventions under investigation include: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel) (DRUG).
Who is sponsoring clinical trial NCT00907101?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00907101 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00907101's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia